Health Highlights: July 2, 2018
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Court Blocks Kentucky's Medicaid Work Rules
Kentucky's plan to require many Medicaid recipients to work, get job training or volunteer has been blocked by a federal judge.
The Trump administration's approval of the plan was "arbitrary and capricious" because it did not fully weigh whether the plan would "help the state furnish medical assistance to its citizens, a central objective of Medicaid," Judge James E. Boasberg of Federal District Court for the District of Columbia rule Friday, The New York Times reported.
Implementation of the plan had been scheduled to begin next week and completed by the end of the year.
Republican Gov. Matt Bevin has said if the courts block the plan, he will end Medicaid expansion in Kentucky. Adam Meier, the state's top health official, said he would work with the Trump administration to "quickly resolve the single issue raised by the court so that we can move forward," The Times reported.
If quick implementation of the plan is not possible, "we will have no choice but to make significant benefit reductions," Meier said.
Three other states have also been given permission by the Trump administration to impose work requirements on Medicaid recipients, and seven more states have asked to do so, The Times reported.
Early Success in Artificial Ovary Research
An early advance in efforts to develop artificial ovaries for women with cancer who are at risk of becoming infertile has been achieved by scientists.
Cancer treatments such as chemotherapy and radiotherapy, can damage the ovaries and leave women infertile. In some cases, all or part of the ovary is removed before those cancer treatments and frozen so that it can be used in the future, BBC News reported.
However, there is a slight risk that the ovarian tissue may contain cancer cells, putting a woman at risk for the return of her cancer.
In this new research, scientists in Denmark removed ovarian follicles and ovarian tissue from women due to have cancer treatment. They removed cancer cells from the ovarian tissue, leaving behind a "scaffold" made up of proteins and collagen, BBC News reported.
The team then grew ovarian follicles on this scaffold of ovarian tissue. This artificial ovary was then transplanted into mice, where the ovarian cells survived and grew.
The research was presented at the annual meeting of the European Society of Human Reproduction and Embryology.
This is an "exciting" technique, but still requires testing in humans, experts said. Such testing is expected to be conducted over the next few years, BBC News reported.
This approach could enable women who've become infertile to get pregnant "naturally", instead of having to rely on in vitro fertilization (IVF), Stuart Lavery, consultant gynecologist, Hammersmith Hospital, U.K., told BBC News.
Another advantage of ovarian tissue transplants is that women who've become infertile due to medical treatments could start having periods again, eliminating the need for hormone replacement therapy, according to Dr. Gillian Lockwood, medical director, Midlands Fertility Services, U.K.
© 2020 HealthDay. All rights reserved.
Posted: July 2018
Read this next
THURSDAY, Oct. 29, 2020 -- Most kids infected with COVID-19 who don't have symptoms have low levels of the virus, compared with symptomatic children, a new study...
THURSDAY, Oct. 29, 2020 -- People have to be told to keep their distance when they're sick, but vampire bats do it naturally, a new study finds. As a disease spreads through a...
THURSDAY, Oct. 29, 2020 -- America's leading infectious diseases expert called for a national mask mandate on Wednesday as coronavirus cases surged across the country. After...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.